Valuation : Roche Holding AG

Market Cap 291B 360B 310B 266B 501B 34,429B 502B 3,453B 1,347B 17,380B 1,353B 1,323B 57,628B P/E 2026 *
20.3x
P/E 2027 * 18x
Enterprise Value 302B 374B 322B 276B 519B 35,715B 521B 3,582B 1,398B 18,029B 1,403B 1,372B 59,780B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 4.51x
Free-Float
88.78%
Yield 2026 *
2.74%
Yield 2027 * 2.81%
1 day-1.69%
1 week-3.58%
Current month+2.06%
1 month-2.03%
3 months+9.12%
6 months-1.93%
Current year+9.19%
1 week 366
Extreme 366
383
1 month 356.6
Extreme 356.6
383
Current year 301.2
Extreme 301.2
383
1 year 264.6
Extreme 264.6
383
3 years 229.4
Extreme 229.4
383
5 years 229.4
Extreme 229.4
439.2
10 years 209.4
Extreme 209.4
439.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-3.58% - - 362B
-0.98%-7.02%+59.47%+110.73% 1,048B
+0.13%-1.58%+51.59%+61.89% 640B
-1.04%-3.45%+23.04%+73.52% 456B
-1.46%-4.50%+37.43%+38.41% 362B
-0.72%-2.89%+21.86%+36.79% 295B
-1.19%-2.21%+1.35%+10.79% 255B
-1.33%-1.77%+51.10%+68.21% 236B
+0.08%-1.78%-17.64%-54.29% 204B
-2.54%-0.69%+28.91%+88.35% 185B
Average -1.03%-0.72%+28.57%+48.27% 409.07B
Weighted average by Cap. -0.93%-1.92%+38.04%+64.68%

Financials

2026 *2027 *
Net sales 62.64B 77.54B 66.81B 57.19B 108B 7,411B 108B 743B 290B 3,741B 291B 285B 12,404B 65.47B 81.04B 69.83B 59.77B 113B 7,745B 113B 777B 303B 3,910B 304B 298B 12,964B
Net income 14.51B 17.95B 15.47B 13.24B 24.95B 1,716B 25.03B 172B 67.15B 866B 67.41B 65.94B 2,872B 16.33B 20.22B 17.42B 14.91B 28.09B 1,932B 28.18B 194B 75.6B 975B 75.9B 74.25B 3,234B
Net Debt 10.87B 13.45B 11.59B 9.92B 18.69B 1,285B 18.75B 129B 50.3B 649B 50.5B 49.4B 2,152B 4.02B 4.98B 4.29B 3.67B 6.91B 475B 6.93B 47.69B 18.61B 240B 18.68B 18.27B 796B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-08-28 CHF 366.00 -2.03% 24,225
26-08-27 CHF 373.60 -0.27% 37,935
26-08-26 CHF 374.60 -1.16% 31,526
26-08-25 CHF 379.00 +0.91% 22,856
26-08-24 CHF 375.60 -1.05% 15,739
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
364.00CHF
Average target price
370.31CHF
Spread / Average Target
+1.73%

Quarterly revenue - Rate of surprise